Approaches to prostatic 5 alpha-reductase inhibitors
Batzold, F.H.
Progress in Clinical and Biological Research 75b: 269-282
1981
ISSN/ISBN: 0361-7742 PMID: 6172801 Document Number: 178714
Document emailed within 1 workday
Related Documents
Djavan, B.; McConnell, J. 1996: The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia Wiener Medizinische Wochenschrift 146(8): 165-168Sun, Z.Y.; Tu, Z.H. 1998: A novel in vitro model to screen steroid 5 alpha-reductase inhibitors against benign prostatic hyperplasia Methods and Findings in Experimental and Clinical Pharmacology 20(4): 283-287
2003: 5-alpha reductase inhibitors plus alpha blockers. A combination therapy keeps a common disease checked MMW Fortschritte der Medizin 145(27-28): 58-59
Reichardt, J.K. 2000: Prostatic steroid 5 alpha-reductase, an androgen metabolic gene Mayo Clinic Proceedings 75 Suppl: S36-S39
Spivak, L.G.; Lokshin, K.L.; Vinarov, A.Z. 2015: Review of Clinical Studies on Combination Therapy of 5α-Reductase Inhibitors and Α1-Blockers in Patients with Benign Prostatic Hyperplasia Urologiia 2015(4): 125-133
Klotz, L.H. 2006: Androgen replacement and/or 5 alpha reductase inhibitors in aging men Canadian Journal of Urology 13(Suppl 1): 44-45
Cohen, J.; Ooms, M.P.; Vreeburg, J.T. 1981: Reduction of fertilizing capacity of epididymal spermatozoa by 5 alpha-steroid reductase inhibitors Experientia 37(9): 1031-1032
Jaworska, L.; Rembiesa, R. 1982: Effect of delta 4-5 alpha-reductase inhibitors on progesterone 4-C-14 metabolism in the rat placenta in vitro Endokrynologia Polska 33(4-6): 183-191
Wu, J-Hui.; Sun, Z-Yue. 2013: Establishment of an in vitro screening model for steroid 5 alpha-reductase inhibitors with the microplate reader Zhonghua Nan Ke Xue 19(6): 483-486
Denti, L.; Pasolini, G.; Cortellini, P.; Sanfelici, L.; Benedetti, R.; Cecchetti, A.; Ferretti, S.; Banchini, A.; Ablondi, F.; Valenti, G. 1999: Effects of 5 alpha-reductase inhibition by finasteride on lipoproteins and body composition in males affected by benign prostatic hyperplasia (BPH) Journal of Endocrinological Investigation 22(10 Suppl): 70-71
Hansen, B.J.; Hvidt, V. 1993: Finasteride. a new 5 alpha reductase inhibitor registered for treatment of benign prostatic hypertrophy with the purpose of avoiding or postponing surgery Ugeskrift for Laeger 155(50): 4110-4112
Yamamoto, A. 2001: HMG-CoA reductase inhibitors Nihon Rinsho. Japanese Journal of Clinical Medicine 59(Suppl 3): 578-586
Davignon, J.; Montigny, M.; Dufour, R. 1992: HMG-CoA reductase inhibitors: a look back and a look ahead Canadian Journal of Cardiology 8(8): 843-864
Tomita, N.; Morishita, R.; Ogihara, T. 2002: Pharmacological effects of HMG-CoA reductase inhibitors Nihon Rinsho. Japanese Journal of Clinical Medicine 60(5): 955-961
Gmiński, J.; Wojakowski, W. 1997: Anti-atherosclerotic actions of HMG-CoA reductase inhibitors Przeglad Lekarski 54(11): 782-787
Fuentes, I.; Aguilera, C. 1998: Myopathy secondary to the treatment with inhibitors of HMG-CoA reductase Medicina Clinica 111(18): 700
Erkelens, D.W.; Bravenboer, B. 1990: Aldose reductase inhibitors in diabetic neuropathy Nederlands Tijdschrift Voor Geneeskunde 134(15): 775-776
Cecha, J.ós.; Drabek, G.; Błazelonis, A.; Romanowski, W.; Zubelewicz-Szkodzińska, B. 2004: The role of HMG-CoA reductase inhibitors in regulation of the inflammatory processes Wiadomosci Lekarskie 57(5-6): 255-258
Bagi, C.M. 2002: HMG-CoA reductase inhibitors - a review of the recent patent literature Idrugs: the Investigational Drugs Journal 5(3): 266-277
Bowden, K.; Harris, N.V.; Watson, C.A. 1993: Structure-activity relationships of dihydrofolate reductase inhibitors Journal of ChemoTherapy 5(6): 377-388